Navigation Links
Uroplasty Reports Fiscal Third Quarter 2013 Financial Results
Date:1/24/2013

from similarly titled measures used by other companies.  Therefore, our non-GAAP financial measures may not be comparable to those used by other companies.  We have described the reconciliations of each of our non-GAAP financial measures described above to the most directly comparable GAAP financial measures.

We use these non-GAAP financial measures, and in particular non-GAAP operating loss, for internal managerial purposes and incentive compensation for senior management because we believe such measures are one important indicator of the strength and the operating performance of our business.  Analysts and investors frequently ask us for this information.  We believe that they use these measures to evaluate the overall operating performance of companies in our industry, including as a means of comparing period-to-period results and as a means of evaluating our results with those of other companies.

Our non-GAAP operating loss during the three months ended December 31, 2012 and 2011 was approximately $135,000 and $570,000, respectively.  Our non-GAAP operating loss during the nine months ended December 31, 2012 and 2011 was approximately $858,000 and $2.3 million, respectively.  The decrease in non-GAAP operating loss for the three months ended December 31, 2012 over the corresponding period a year ago is attributed to the increase in net sales and gross profit percent and the decrease in operating spending.  The decrease in non-GAAP operating loss for the nine months ended December 31, 2012 over the corresponding period a year ago is attributed to the increase in net sales and gross profit percent, which more than offset the increase in operating spending.

 Expense AdjustmentsThree-Months EndedGAAPShare-based  ExpenseDepreciationAmortization of IntangiblesNon-GAAPDecember 31, 2012Gross Profit

$4,856,000

$8,000

$8,000$4,872,000% of net sales

86.9%87.2%Operating Exp
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Uroplasty To Participate In The Oppenheimer 23rd Annual Healthcare Conference
2. Uroplasty To Participate In Two Upcoming Investor Conferences
3. Uroplasty Reports Fiscal Second Quarter 2013 Financial Results
4. Uroplasty To Participate In Two Upcoming Conferences
5. Uroplasty Reports Fiscal First Quarter 2013 Financial Results
6. Uroplasty to Issue First Quarter of Fiscal 2013 Financial Results on July 26, 2012
7. Uroplasty To Present At The JMP Securities Healthcare Conference
8. Uroplasty Reports Fiscal Fourth Quarter And Full Year 2012 Financial Results
9. Uroplasty Announces Product Development and New Clinical Trial Initiatives
10. Uroplasty to Present at the 11th Annual JMP Securities Research Conference
11. Cepheid Reports Fourth Quarter And Full Year 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), ... that its VENTANA System for Primary Diagnosis 1 ... Union for routine pathology, including primary diagnosis with ... Virtuoso software coupled with either the VENTANA iScan ... provides automated digital slide creation, case management and ...
(Date:8/20/2014)... BURLINGTON, Mass. , Aug. 20, 2014 ... Japanese electrophysiology (EP) mapping and ablation device ... increasingly use ablation to treat atrial fibrillation ... a primary treatment option for AF will ... for this application, such as advanced loop ...
(Date:8/20/2014)... 2014  Amerigen Pharmaceuticals Ltd. announces that its ... received Chinese FDA (CFDA) approval and has subsequently ... the China domestic market.  ... agreement with Sinochem Jiangsu Pharmaceutical Co., Ltd., Amerigen ... approved and China CFDA certified oral solid dose ...
Breaking Medicine Technology:Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2
... Sequenom, Inc. (Nasdaq: SQNM ) today announced ... company at the following conferences in November. ... ) Lazard Capital Markets 7th Annual ... York, NY Presentation date: Tuesday November 16, 2010 ...
... Pharmaceuticals today announced it has discovered that EVP-6124, its ... not previously seen in the scientific community: it acts ... By acting as a co-agonist and sensitizing ... amounts of naturally occurring ACh, typically found in individuals ...
Cached Medicine Technology:Sequenom to Present at Two Financial Conferences in November 2EnVivo Pharmaceuticals Research Shows EVP-6124 Acts as Acetylcholine Co-Agonist 2EnVivo Pharmaceuticals Research Shows EVP-6124 Acts as Acetylcholine Co-Agonist 3
(Date:8/20/2014)... made it easier to predict both breast cancer ... of a unique gene. The newly found marker ... and customise a treatment regimen that is more ... scientists from A*STAR,s Institute of Molecular and Cell ... Singapore (CSI Singapore) at the National University of ...
(Date:8/20/2014)... The Institute for Integrative Nutrition ... to announce its new partnership with California ... university offering graduate programs featuring flexible learning. Graduates ... now eligible to receive six graduate credits towards ... , “I’m so thrilled to announce this new ...
(Date:8/20/2014)... "I decided that there needed to be a ... without the hassles associated with using conventional oral devices," ... DR. GATES ORAL-HYGIENE TOOL provides an easy way to ... oral hygiene and fresh breath, and it eliminates the ... eco-friendly and easy to use, the device is producible ...
(Date:8/20/2014)... extracted acellular allogeneic nerve, from which Schwann ... been removed, reduced postoperative immune rejection. Simultaneously, ... substrates and base materials, such as the ... provide a good scaffold in the process ... nerve, similar to autologous nerve transplantation, can ...
(Date:8/20/2014)... 20, 2014 Doctors at the University of ... out mesothelioma in laboratory mice by injecting them with a ... details of the study on its website. Click here ... Hong Kong University’s AIDS Institute of Microbiology created a vaccine ... PD-1. By altering DNA, the vaccine is designed to prevent ...
Breaking Medicine News(10 mins):Health News:Novel gene predicts both breast cancer relapse and response to chemotherapy 2Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 2Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 3Health News:New Research Study Finds Vaccine Stops Mesothelioma in Lab Mice, According to Surviving Mesothelioma Website 2
... cuts side effects , , MONDAY, May 11 (HealthDay ... mesylate (CM) to the conventional two-drug regimen of ... vomiting (CINV) in patients undergoing highly emetogenic chemotherapy ... used to treat many types of solid tumor ...
... DNA offers insights to better treatments, scientists say , , ... studies have identified what researchers describe as a treasure ... "In one fell swoop, to find so many genes ... the lead author of one of the studies, Dr. ...
... for People with Epilepsy Now Accepting EntriesTITUSVILLE, N.J., May ... for centuries, with most agreeing that art means something ... can be a self-expressive, visual demonstration of how it ... Expressions of Courage (R) is a national contest for ...
... mild , , MONDAY, May 11 (HealthDay News) -- Confirmed ... to more than 2,500 by Monday, and the U.S. now ... according to World Health Organization figures. , The number of ... the weekend, with health officials in Washington state reporting late ...
... MedCath Corporation (Nasdaq: MDTH ), ... services, predominately the diagnosis and treatment of cardiovascular ... its senior management team as Senior Vice President, ... hospitals located in Arizona, California, New Mexico as ...
... Shaver, will be an invited panelist in the second annual SOA in ... Illinois. , ... Plano, Texas (PRWEB) May 11, 2009-- Corepoint Health,s CTO, ... in Healthcare conference to be held on June 2 - 4 in ...
Cached Medicine News:Health News:3-Drug Combo Reduces Nausea After Chemo 2Health News:Genes Yield Clues to High Blood Pressure 2Health News:Genes Yield Clues to High Blood Pressure 3Health News:Every Picture Tells A Story, Particularly for Those With Epilepsy 2Health News:Every Picture Tells A Story, Particularly for Those With Epilepsy 3Health News:U.S. Now Leads World in Swine Flu Cases 2Health News:U.S. Now Leads World in Swine Flu Cases 3Health News:U.S. Now Leads World in Swine Flu Cases 4Health News:U.S. Now Leads World in Swine Flu Cases 5Health News:U.S. Now Leads World in Swine Flu Cases 6Health News:U.S. Now Leads World in Swine Flu Cases 7Health News:U.S. Now Leads World in Swine Flu Cases 8Health News:U.S. Now Leads World in Swine Flu Cases 9Health News:U.S. Now Leads World in Swine Flu Cases 10Health News:U.S. Now Leads World in Swine Flu Cases 11Health News:David Covert to Join MedCath as Senior Vice President, Operations 2Health News:Corepoint Health CTO to Participate in Panel Discussion at the 2009 SOA in Healthcare Conference 2Health News:Corepoint Health CTO to Participate in Panel Discussion at the 2009 SOA in Healthcare Conference 3
Stylish yet conservative, these classics are reliable, comfortable and durable....
Safilo Design, a state-of-the art ophthalmic collection that blends technology with minimalist sophistication. Each style comes with a sleek silver-colored hard case with magnetic closure....
Inquire...
Classic, stylish, and preppy, this collection features men's, women's and unisex styles....
Medicine Products: